Back to top
more

Glaukos (GKOS)

(Delayed Data from NYSE)

$119.82 USD

119.82
617,615

+2.17 (1.84%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $119.74 -0.08 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (100 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Accuray (ARAY) Incurs Wider Loss in Q2, Misses on Revenue

Accuray Inc. (ARAY) reported a loss of 11 cents per share in the second quarter of fiscal 2017, wider than the Zacks Consensus Estimate of a loss of 7 cents.

    Align Technology (ALGN) Q4 Earnings and Revenues in Line

    Align Technology Inc. (ALGN) reported adjusted earnings of 67 cents per share in the fourth quarter of 2016, up 11.6% from 60 cents in the year-ago quarter.

      Illumina (ILMN) Beats Q4 Earnings & Revenues, Guides 2017

      Illumina Inc. (ILMN) reported adjusted earnings per share (EPS) of 85 cents in the fourth quarter of 2016, which exceeded the Zacks Consensus Estimate by 4.9%.

        Zimmer Biomet (ZBH) Beats on Q4 Earnings, Knees Improve

        Zimmer Biomet Holdings, Inc. (ZBH) reported fourth-quarter 2016 adjusted earnings per share (EPS) of $2.14, up 2.4% year over year.

          Hill-Rom TruSystem 3000 Table Boosts Surgical Solution Suite

          Hill-Rom Holdings (HRC) recently launched TruSystem 3000 Mobile Operating Table to fulfill hospitals' need to equip operating rooms with quality medical devices at a reasonable cost.

            Thermo Fisher (TMO) Q4 Earnings Beat, Organic Sales Flat

            Thermo Fisher Scientific, Inc. (TMO) reported better-than-expected fourth-quarter and full-year 2016 earnings results.

              Abiomed (ABMD) Beats Earnings & Revenue Estimates in Q3

              Abiomed Inc. (ABMD) reported third-quarter fiscal 2017 earnings of 34 cents per share, which surpassed the Zacks Consensus Estimate by 5 cents and surged 47.8% from the year-ago quarter.

                C.R. Bard (BCR) Q4 Earnings & Sales Better Than Expected

                C.R. Bard Inc. (BCR) reported adjusted earnings of $2.77 in the fourth quarter of 2016, exceeding the Zacks Consensus Estimate by 4 cents and improving from the year-ago quarterly number of $2.43.

                  Quality Systems (QSII) Beats on Earnings & Revenues in Q3

                  Irvine, CA-based Quality Systems Inc. (QSII) reported third-quarter fiscal 2017 adjusted earnings of 21 cents per share, exceeding the Zacks Consensus Estimate of 18 cents.

                    Varian Medical (VAR) Misses on Q1 Earnings and Revenues

                    Varian Medical Systems, Inc. (VAR) reported adjusted earnings of 75 cents per share in the first quarter of fiscal 2017.

                      McKesson (MCK) Beats on Earnings in Q3, Inks Buyout Deal

                      McKesson Corporation (MCK) reported third-quarter fiscal 2017 earnings of $3.03 per share, beating the Zacks Consensus Estimate of $2.95 but declining from the year-ago figure of $3.18.

                        Stryker (SYK) Beats Q4 Earnings, Provides FY17 Guidance

                        Maintaining its streak of positive earnings surprises, Stryker Corp (SYK) reported adjusted earnings of $1.78 per share in the fourth quarter of 2016, which comfortably beat the Zacks Consensus Estimate by 2 cents.

                          Cynosure (CYNO) Looks Good: Stock Adds 6.6% in Session

                          Cynosure, Inc. (CYNO) shares rose over 6% in the last trading session.

                            Can Glaukos (GKOS) Stock Continue to Grow Earnings?

                            Glaukos (GKOS) has a favorable Zacks Rank and is a fast-growing stock that is well positioned for future earnings growth.

                              Zacks.com featured highlights: Glaukos, Apogee Enterprises, Braskem SA, Sundance Energy Australia and Angang Steel

                              Zacks.com featured highlights: Glaukos, Apogee Enterprises, Braskem SA, Sundance Energy Australia and Angang Steel

                                Becton, Dickinson Commercially Launches Precise WTA Kits

                                Becton, Dickinson and Company (BDX), popularly known as BD, recently announced that it has made its Precise whole transcriptome analysis kits commercial available.

                                  Baxter (BAX): Sluggish Macro Environment Mars Prospects

                                  On Jan 17, we issued an updated research report on Deerfield, IL-based Baxter International Inc. (BAX), a global medical technology company and leading provider of renal and hospital products.

                                    Zacks.com featured highlights: Glaukos, Daqo New Energy, Calavo Growers and Sucampo Pharmaceuticals

                                    Zacks.com featured highlights: Glaukos, Daqo New Energy, Calavo Growers and Sucampo Pharmaceuticals

                                      Medidata Solutions Clinical Cloud Gets Picked by Celgene

                                      Medidata Solutions Inc. (MDSO) recently announced that Celgene Corporation adopted Medidata Clinical Cloud.

                                        Pacific Biosciences (PACB) to Sell 10 PacBio Sequel Systems

                                        Pacific Biosciences of California, Inc. (PACB), announced that it will sell 10 PacBio Sequel Systems to Novogene Bioinformatics Technology Company, Ltd.

                                          5 Stocks with Recent Price Strength to Boost Your Returns

                                          One should primarily target stocks that have recently been on a bullish run. Actually, stocks seeing price strength recently have a high chance of carrying the momentum forward.

                                            Akers Biosciences (AKER) Closes Offering of 1.7M Shares

                                            Akers Biosciences, Inc. (AKER) recently announced the closing of a public offering of 1.7 million common shares.

                                              4 Profitable Stocks with Amazingly High Returns

                                              Net income ratio gives us the exact profitability level of a company and reflects the percentage of net income to total sales revenue.

                                                Intuitive Surgical (ISRG) Expects Strong Revenues in Q4

                                                Intuitive Surgical, Inc. (ISRG) announced that it expects fourth-quarter 2016 revenues of approximately $757 million.

                                                  Fluidigm: Q4 Preliminary Results Fail to Cheer Investors

                                                  The market is not really happy with South San Francisco, CA-based Fluidigm Corporation's (FLDM) preliminary results for the fourth quarter and full-year 2016.